Advancements in Drug Discovery Using Computational Modeling

This technical report discusses advancements in drug discovery through the application of physics-based computational modeling. It outlines multiple oncology programs that showcase the integration of molecular dynamics, free energy calculations, and quantum mechanics. The report describes the development of clinical-stage compounds, including the MALT1 inhibitor SGR-1505, which demonstrates potent inhibition in specific cancer cell lines, and the CDC7 inhibitor SGR-2921, which shows selectivity and induction of apoptosis in cancer cells. Additionally, the WEE1/Myt1 inhibitor SGR-3515 is detailed, highlighting its performance in preclinical models. The document also emphasizes ongoing research into synthetic lethality and novel molecule design, aimed at enhancing treatment potential in various cancers. It elaborates on the utilization of advanced computational tools that facilitate the exploration of chemical space, optimize compounds, and improve therapeutic outcomes across a range of oncology targets.